J Neuroinflammation
Published

Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.

Authors

Aurora Veteleanu, Joshua Stevenson-Hoare, Samuel Keat, Nikoleta Daskoulidou, Henrik Zetterberg, Amanda Heslegrave, Valentina Escott-Price, Julie Williams, Rebecca Sims, Wioleta M Zelek, Sarah M Carpanini, Bryan Paul Morgan
Read More

Abstract

Alzheimer's disease (AD) has been associated with immune dysregulation in biomarker and genome-wide association studies (GWAS). GWAS hits include the genes encoding complement regulators clusterin (CLU) and complement receptor 1 (CR1), recognised as key players in AD pathology, and complement proteins have been proposed as biomarkers.

PMID:37480051 | DOI:10.1186/s12974-023-02850-6

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
Amanda Heslegrave

Dr Amanda Heslegrave

Principal Research Fellow

Co-leading the UK DRI Biomarker Factory platform based at UK DRI at UCL

Dr Amanda Heslegrave
Valentina Escott-Price

Prof Valentina Escott-Price

Group Leader

Using Big Data, machine learning and AI to accelerate discoveries into dementia

Prof Valentina Escott-Price
Julie Williams

Prof Julie Williams

Group Leader

Understanding the genetics of Alzheimer's disease

Prof Julie Williams